Datta R, Naura AS, Zerfaoui M, Errami Y, Oumouna M, Kim H, et al.(2011). PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model. Allergy 66: 853-861.

Drosten C, Preiser W, Gunther S, Schmitz H, & Doerr HW (2003). Severe acute respiratory syndrome: identification of the etiological agent. Trends Mol Med 9: 325-327.

Fehr AR, Singh SA, Kerr CM, Mukai S, Higashi H, & Aikawa M (2020). The impact of PARPs and ADP-ribosylation on inflammation and host-pathogen interactions. Genes Dev 34: 341-359.

Fung TS, & Liu DX (2019). Human Coronavirus: Host-Pathogen Interaction. Annu Rev Microbiol 73: 529-557.

Ge Y, Tian T, Huang S, Wan F, Li J, Li S, et al. (2020). A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19.

Genovese T, Mazzon E, Di Paola R, Muia C, Threadgill MD, Caputi AP, et al. (2005). Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and the development of bleomycin-induced lung injury. J Pharmacol Exp Ther 313:529-538.

Gero D, Szoleczky P, Chatzianastasiou A, Papapetropoulos A, & Szabo C (2014). Modulation of poly(ADP-ribose) polymerase-1 (PARP-1)-mediated oxidative cell injury by ring finger protein 146 (RNF146) in cardiac myocytes. Mol Med 20: 313-328.

Gharote M (2020). Role of PARP-1 inhibition by nicotinamide to modulate host immune response and prevention of cytokine storm in COVID-19. Indian Journal of Medical Sciences 72: 21-24.

Ghonim MA, Pyakurel K, Ibba SV, Wang J, Rodriguez P, Al-Khami AA, et al. (2015). PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice. Clin Sci (Lond) 129: 951-962.

Grady SL, Hwang J, Vastag L, Rabinowitz JD, & Shenk T (2012). Herpes simplex virus 1 infection activates poly(ADP-ribose) polymerase and triggers the degradation of poly(ADP-ribose) glycohydrolase. J Virol 86: 8259-8268.

Grunewald ME, Chen Y, Kuny C, Maejima T, Lease R, Ferraris D, et al. (2019). The coronavirus macrodomain is required to prevent PARP-mediated inhibition of virus replication and enhancement of IFN expression. PLoS Pathog 15: e1007756.

Grunewald ME, Fehr AR, Athmer J, & Perlman S (2018). The coronavirus nucleocapsid protein is ADP-ribosylated. Virology 517: 62-68.

Ha HC, Juluri K, Zhou Y, Leung S, Hermankova M, & Snyder SH (2001). Poly(ADP-ribose) polymerase-1 is required for efficient HIV-1 integration. Proc Natl Acad Sci U S A 98: 3364-3368.

Hans CP, Zerfaoui M, Naura AS, Troxclair D, Strong JP, Matrougui K, et al. (2009). Thieno[2,3-c]isoquinolin-5-one, a potent poly(ADP-ribose) polymerase inhibitor, promotes atherosclerotic plaque regression in high-fat diet-fed apolipoprotein E-deficient mice: effects on inflammatory markers and lipid content. J Pharmacol Exp Ther 329: 150-158.

Hassa PO (2009). The molecular ”Jekyll and Hyde” duality of PARP1 in cell death and cell survival. Front Biosci (Landmark Ed) 14:72-111.

Hassumi-Fukasawa MK, Miranda-Camargo FA, Zanetti BR, Galano DF, Ribeiro-Silva A, & Soares EG (2012). Expression of BAG-1 and PARP-1 in precursor lesions and invasive cervical cancer associated with human papillomavirus (HPV). Pathol Oncol Res 18: 929-937.

Hori S, Nomura T, & Sakaguchi S (2017). Pillars Article: Control of Regulatory T Cell Development by the Transcription Factor Foxp3. Science 2003. 299: 1057-1061. J Immunol 198: 981-985.

Hu B, Wu Z, Hergert P, Henke CA, Bitterman PB, & Phan SH (2013). Regulation of myofibroblast differentiation by poly(ADP-ribose) polymerase 1. Am J Pathol 182: 71-83.

Jagtap P, & Szabo C (2005). Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4:421-440.

Kaundal RK, Shah KK, & Sharma SS (2006). Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation. Life Sci 79:2293-2302.

Kauppinen TM, Suh SW, Berman AE, Hamby AM, & Swanson RA (2009). Inhibition of poly(ADP-ribose) polymerase suppresses inflammation and promotes recovery after ischemic injury. J Cereb Blood Flow Metab 29: 820-829.

Kim JH, Suk MH, Yoon DW, Kim HY, Jung KH, Kang EH, et al. (2008). Inflammatory and transcriptional roles of poly (ADP-ribose) polymerase in ventilator-induced lung injury. Crit Care 12: R108.

King TE, Jr., Pardo A, & Selman M (2011). Idiopathic pulmonary fibrosis. Lancet 378: 1949-1961.

Ko HL, Ng HJ, Goh EH, & Ren EC (2013). Reduced ADP-ribosylation by PARP1 natural polymorphism V762A and by PARP1 inhibitors enhance Hepatitis B virus replication. J Viral Hepat 20: 658-665.

Kumar M, Seeger W, & Voswinckel R (2014). Senescence-associated secretory phenotype and its possible role in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 51: 323-333.

Liaudet L, Pacher P, Mabley JG, Virag L, Soriano FG, Hasko G, et al. (2002). Activation of poly(ADP-Ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Am J Respir Crit Care Med 165: 372-377.

Liu L, Lear Z, Hughes DJ, Wu W, Zhou EM, Whitehouse A, et al.(2015). Resolution of the cellular proteome of the nucleocapsid protein from a highly pathogenic isolate of porcine reproductive and respiratory syndrome virus identifies PARP-1 as a cellular target whose interaction is critical for virus biology. Vet Microbiol 176: 109-119.

Lucarini L, Durante M, Lanzi C, Pini A, Boccalini G, Calosi L, et al. (2017). HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-beta/SMAD signalling pathway. J Cell Mol Med 21: 324-335.

Luo X, Nie J, Wang S, Chen Z, Chen W, Li D, et al. (2015). Poly(ADP-ribosyl)ation of FOXP3 Protein Mediated by PARP-1 Protein Regulates the Function of Regulatory T Cells. J Biol Chem 290:28675-28682.

Lupey-Green LN, Caruso LB, Madzo J, Martin KA, Tan Y, Hulse M, et al. (2018). PARP1 Stabilizes CTCF Binding and Chromatin Structure To Maintain Epstein-Barr Virus Latency Type. J Virol 92.

Lupey-Green LN, Moquin SA, Martin KA, McDevitt SM, Hulse M, Caruso LB, et al. (2017). PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter. Virology 507:220-230.

MacNee W (2001). Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 429: 195-207.

Malik YA (2020). Properties of Coronavirus and SARS-CoV-2. Malays J Pathol 42: 3-11.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395: 1033-1034.

Moroni F, Cozzi A, Chiarugi A, Formentini L, Camaioni E, Pellegrini-Giampietro DE, et al. (2012). Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase. Br J Pharmacol 165: 1487-1500.

Mota RA, Hernandez-Espinosa D, Galbis-Martinez L, Ordonez A, Minano A, Parrilla P, et al. (2008). Poly(ADP-ribose) polymerase-1 inhibition increases expression of heat shock proteins and attenuates heat stroke-induced liver injury. Crit Care Med 36: 526-534.

Mukhopadhyay P, Rajesh M, Cao Z, Horvath B, Park O, Wang H, et al. (2014). Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. Hepatology 59: 1998-2009.

Na TY, Ka NL, Rhee H, Kyeong D, Kim MH, Seong JK, et al. (2016). Interaction of hepatitis B virus X protein with PARP1 results in inhibition of DNA repair in hepatocellular carcinoma. Oncogene 35: 5435-5445.

Naura AS, Hans CP, Zerfaoui M, You D, Cormier SA, Oumouna M, et al. (2008). Post-allergen challenge inhibition of poly(ADP-ribose) polymerase harbors therapeutic potential for treatment of allergic airway inflammation. Clin Exp Allergy 38: 839-846.

Oumouna M, Datta R, Oumouna-Benachour K, Suzuki Y, Hans C, Matthews K, et al. (2006). Poly(ADP-ribose) polymerase-1 inhibition prevents eosinophil recruitment by modulating Th2 cytokines in a murine model of allergic airway inflammation: a potential specific effect on IL-5. J Immunol 177: 6489-6496.

Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. (2020). Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J Med.

Petrakis D, Margina D, Tsarouhas K, Tekos F, Stan M, Nikitovic D, et al. (2020). Obesity a risk factor for increased COVID19 prevalence, severity and lethality (Review). Mol Med Rep.

Rajawat J, Shukla N, & Mishra DP (2017a). Poly(ADP-Ribose) polymerase 1: a therapeutic hope in gynecologic cancers. Front Biosci (Schol Ed) 9: 343-356.

Rajawat J, Shukla N, & Mishra DP (2017b). Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities. Med Res Rev 37: 1461-1491.

Rajawat J, Vohra I, Mir HA, Gohel D, & Begum R (2007). Effect of oxidative stress and involvement of poly(ADP-ribose) polymerase (PARP) in Dictyostelium discoideum development. FEBS J 274: 5611-5618.

Reinemund J, Seidel K, Steckelings UM, Zaade D, Klare S, Rompe F, et al. (2009). Poly(ADP-ribose) polymerase-1 (PARP-1) transcriptionally regulates angiotensin AT2 receptor (AT2R) and AT2R binding protein (ATBP) genes. Biochem Pharmacol 77: 1795-1805.

Rom S, Reichenbach NL, Dykstra H, & Persidsky Y (2015). The dual action of poly(ADP-ribose) polymerase -1 (PARP-1) inhibition in HIV-1 infection: HIV-1 LTR inhibition and diminution in Rho GTPase activity. Front Microbiol 6: 878.

Rom S, Zuluaga-Ramirez V, Reichenbach NL, Dykstra H, Gajghate S, Pacher P, et al. (2016). PARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier. J Neuroinflammation 13: 254.

Shou Q, Fu H, Huang X, & Yang Y (2019). PARP-1 controls NK cell recruitment to the site of viral infection. JCI Insight 4.

Stanisavljevic J, Porta-de-la-Riva M, Batlle R, de Herreros AG, & Baulida J (2011). The p65 subunit of NF-kappaB and PARP1 assist Snail1 in activating fibronectin transcription. J Cell Sci 124:4161-4171.

Sun J, He WT, Wang L, Lai A, Ji X, Zhai X, et al. (2020). COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives. Trends Mol Med 26: 483-495.

Suzuki T, Nishi T, Nagino T, Sasaki K, Aizawa K, Kada N, et al.(2007). Functional interaction between the transcription factor Kruppel-like factor 5 and poly(ADP-ribose) polymerase-1 in cardiovascular apoptosis. J Biol Chem 282: 9895-9901.

Teng F, Beray-Berthat V, Coqueran B, Lesbats C, Kuntz M, Palmier B, et al. (2013). Prevention of rt-PA induced blood-brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice. Exp Neurol 248: 416-428.

Vaschetto R, Kuiper JW, Chiang SR, Haitsma JJ, Juco JW, Uhlig S, et al. (2008). Inhibition of poly(adenosine diphosphate-ribose) polymerase attenuates ventilator-induced lung injury. Anesthesiology 108: 261-268.

von Lukowicz T, Hassa PO, Lohmann C, Boren J, Braunersreuther V, Mach F, et al. (2008). PARP1 is required for adhesion molecule expression in atherogenesis. Cardiovasc Res 78: 158-166.

Westera L, Jennings AM, Maamary J, Schwemmle M, Garcia-Sastre A, & Bortz E (2019). Poly-ADP Ribosyl Polymerase 1 (PARP1) Regulates Influenza A Virus Polymerase. Adv Virol 2019: 8512363.

Xia C, Wolf JJ, Sun C, Xu M, Studstill CJ, Chen J, et al. (2020). PARP1 Enhances Influenza A Virus Propagation by Facilitating Degradation of Host Type I Interferon Receptor. J Virol 94.

Yu D, Liu R, Yang G, & Zhou Q (2018). The PARP1-Siah1 Axis Controls HIV-1 Transcription and Expression of Siah1 Substrates. Cell Rep 23: 3741-3749.

Zerfaoui M, Naura AS, Errami Y, Hans CP, Rezk BM, Park J, et al.(2009). Effects of PARP-1 deficiency on airway inflammatory cell recruitment in response to LPS or TNF: differential effects on CXCR2 ligands and Duffy Antigen Receptor for Chemokines. J Leukoc Biol 86: 1385-1392.